ConductScience.org, home

Paper42201461

High-dose dexamethasone and prolonged infusion time prevent oxaliplatin-related hypersensitivity reactions in patients with metastatic colorectal cancer.

Yoshino K and 10 others. Int J Clin Oncol, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. High-dose dexamethasone and prolonged infusion time prevent oxaliplatin-related hypersensitivity reactions in patients with metastatic colorectal cancer. Papers, record 42201461. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42201461

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
High-dose dexamethasone and prolonged infusion time prevent oxaliplatin-related hypersensitivity reactions in patients with metastatic colorectal cancer.
PubMed
Journal
Int J Clin Oncol
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Colorectal NeoplasmsMajor topic
DexamethasoneMajor topic
OxaliplatinMajor topic
Drug HypersensitivityMajor topic
Humans
Female
Male
Aged
Middle Aged
Antineoplastic Combined Chemotherapy Protocols
Adult
Retrospective Studies
Aged, 80 and over
Neoplasm Metastasis
Infusions, Intravenous
Leucovorin
Fluorouracil
Organoplatinum Compounds

Source PubMed

Download CSV of topics

References44

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132880601Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.JAMA Oncol2020https://conductscience.org/library/papers/32880601PubMed
236701137Rechallenge After Oxaliplatin-Induced Hypersensitivity Reactions.JAMA Oncol2023https://conductscience.org/library/papers/36701137PubMed
333724754Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw2021https://conductscience.org/library/papers/33724754PubMed
436252154Treatment of Metastatic Colorectal Cancer: ASCO Guideline.J Clin Oncol2023https://conductscience.org/library/papers/36252154PubMed
534102137
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Lancet2021https://conductscience.org/library/papers/34102137PubMed
620728210
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Lancet2010https://conductscience.org/library/papers/20728210PubMed
712888815Hypersensitivity reactions related to oxaliplatin (OHP).Br J Cancer2003https://conductscience.org/library/papers/12888815PubMed
88156529Hypersensitivity reactions to carboplatin. Report of two patients, review of the literature, and discussion of diagnostic procedures and management.Cancer1994https://conductscience.org/library/papers/8156529PubMed
924286446Immediate-type hypersensitivity drug reactions.Br J Clin Pharmacol2014https://conductscience.org/library/papers/24286446PubMed
1022987983Prevention and handling of acute allergic and infusion reactions in oncology.Ann Oncol2012https://conductscience.org/library/papers/22987983PubMed
1122855191Effectiveness of oxaliplatin desensitization protocols.Clin Transl Oncol2013https://conductscience.org/library/papers/22855191PubMed
127828281Hypersensitivity and cross-reactivity to cisplatin and analogues.Cancer Chemother Pharmacol1995https://conductscience.org/library/papers/7828281PubMed
1331102054Oxaliplatin-desensitization procedure is safe and feasible in an outpatient cancer unit in France.Support Care Cancer2019https://conductscience.org/library/papers/31102054PubMed
1416421419OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.J Clin Oncol2006https://conductscience.org/library/papers/16421419PubMed
1519739272Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol.Clin Colorectal Cancer2009https://conductscience.org/library/papers/19739272PubMed
161277442Immediate (type I) allergic responses to platinum compounds.Clin Allergy1976https://conductscience.org/library/papers/1277442PubMed
1725862137Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol.Clin Ther2015https://conductscience.org/library/papers/25862137PubMed
182348469Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate.J Natl Cancer Inst1990https://conductscience.org/library/papers/2348469PubMed
1922576054Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization.Cancer Immunol Immunother2012https://conductscience.org/library/papers/22576054PubMed
2033538338Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin2021https://conductscience.org/library/papers/33538338PubMed

See all 44 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42201461

GET https://conductscience.org/api/papers/v1/42201461/references?page=2